Table 3.
Summary of human, animal, and cell findings from this study for miRNA associated with PC groups.
| RNAseq of beneficial |
RT-qPCR validation |
Mouse model I/R |
In vitro |
Cell type |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| vs adverse remodelers (n = 11 patients per group) |
(331 patients) |
LV tissue |
Plasma |
hypox/reox (NRVMs) |
Expression (Adult wild-type mice) |
||||||||
| Fold change | P value | PC1 (ΔLV) | PC2 (LVEF) | PC3 (ECV) | 24 h | 1 week | 4 weeks | 24 h | 1 week | 4 weeks | Media EVs | Predominant cell type | |
| miR-21-5p | 1.96 | 0.13 | X | X | 7.2**** | 8.5* | 16.3**** | 10.3* | FB/EC | ||||
| miR-29a-3p | 0.49 | 0.09 | X | 10.4*** | FB/EC | ||||||||
| miR-29b-3p | 0.23 | 0.09 | X | 4.7* | CM/EC | ||||||||
| miR-29c-3p | 0.24 | 0.05 | X | 374.1**** | 52.8**** | CM | |||||||
| miR-30a-5p | 0.4 | 0.05 | X | X | 162.0**** | 20.2** | 15.8* | CM | |||||
| miR-30d-5p | 0.94 | 0.86 | X | X | 92.3**** | 10.8** | 8.7* | CM | |||||
| miR-100-5p | 0.4 | 0.09 | X | 9.0*** | 6.7* | CM/FB | |||||||
| miR-146a-5p | 2.36 | 0.04 | X | 133.0**** | 18.3*** | Non-CM | |||||||
| miR-146b-5p | 2.36 | 0.08 | X | 377.3**** | 15.2* | Non-CM | |||||||
| miR-150-5p | 0.08 | 0.04 | X | 165.2**** | 8.3 | Non-CM | |||||||
| miR-194-5p | 0.18 | 0.04 | X | 14.8**** | 2.6* | CM/non-CM | |||||||
| miR-223-3p | 0.6 | 0.58 | X | 325.4*** | 3.9** | Non-CM | |||||||
| miR-378c | 0.26 | 0.09 | X | 78.4**** | 31.3** | CM | |||||||
| miR-423-5p | 0.91 | 0.85 | X | 9.7**** | 4.3* | FB/EC | |||||||
| miR-744-5p | 2.11 | 0.06 | X | 169.2*** | EC | ||||||||
In relation to poor remodellers (i.e. positive number = increased in poor remodeller).
Fold change vs baseline, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, Student's t-test.